BENVENUTI, SILVIA
BENVENUTI, SILVIA
Dip. SCIENZE ONCOLOGICHE - Candiolo (attivo dal 01/01/2002 al 30/04/2013)
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.
2014-01-01 Benvenuti S;Gentile A;Lazzari L;Arnesano A;Trusolino L;Comoglio PM
Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues
2006-01-01 Salvatore Siena; Mauro Moroni; Giovanna Marrapese; Andrea Sartore-Bianchi; Silvio Veronese; Marcello Gambacorta; Silvia Benvenuti; Federica Di Nicolantonio; Alberto Bardelli
Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report
2020-01-01 Benvenuti S.; Milan M.; Geuna E.; Pisacane A.; Senetta R.; Gambardella G.; Stella G.M.; Montemurro F.; Sapino A.; Boccaccio C.; Comoglio P.M.
Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
2023-01-01 Pisacane, Alberto; Cascardi, Eliano; Berrino, Enrico; Polidori, Alessio; Sarotto, Ivana; Casorzo, Laura; Panero, Mara; Boccaccio, Carla; Verginelli, Federica; Benvenuti, Silvia; Dellino, Miriam; Comoglio, Paolo; Montemurro, Filippo; Geuna, Elena; Marchiò, Caterina; Sapino, Anna
MET mutations in cancers of unknown primary origin (CUPs).
2011-01-01 G. M. Stella;S. Benvenuti;D. Gramaglia;A. Scarpa;A. Tomezzoli;P. Cassoni;R. Senetta;T. Venesio;E. Pozzi;A. Bardelli;P. M. Comoglio
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: An in vitro study
2019-01-01 Cova E.; Pandolfi L.; Colombo M.; Frangipane V.; Inghilleri S.; Morosini M.; Mrakic-Sposta S.; Moretti S.; Monti M.; Pignochino Y.; Benvenuti S.; Prosperi D.; Stella G.; Morbini P.; Meloni F.
Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
2023-01-01 Pisacane, Alberto; Cascardi, Eliano; Berrino, Enrico; Polidori, Alessio; Sarotto, Ivana; Casorzo, Laura; Panero, Mara; Boccaccio, Carla; Verginelli, Federica; Benvenuti, Silvia; Dellino, Miriam; Comoglio, Paolo; Montemurro, Filippo; Geuna, Elena; Marchio', Caterina; Sapino, Anna
Ron kinase transphosphorylation sustains MET oncogene addiction
2011-01-01 S. Benvenuti; L. Lazzari; A. Arnesano; G. Li Chiavi; A. Gentile; P.M. Comoglio
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis
2011-01-01 Gentile A; Lazzari L; Benvenuti S; Trusolino L*; Comoglio PM* (*Corresponding Authors)
Targeting the MET oncogene in cancer and metastases.
2010-01-01 G. M. Stella;S. Benvenuti;P. M. Comoglio
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.
2014-01-01 Gentile A;Lazzari L;Benvenuti S;Trusolino L;Comoglio PM
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. | 2014 | Benvenuti S;Gentile A;Lazzari L;Arnesano A;Trusolino L;Comoglio PM | |
| Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues | 2006 | Salvatore Siena; Mauro Moroni; Giovanna Marrapese; Andrea Sartore-Bianchi; Silvio Veronese; Marcello Gambacorta; Silvia Benvenuti; Federica Di Nicolantonio; Alberto Bardelli | |
| Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report | 2020 | Benvenuti S.; Milan M.; Geuna E.; Pisacane A.; Senetta R.; Gambardella G.; Stella G.M.; Montemurro F.; Sapino A.; Boccaccio C.; Comoglio P.M. | |
| Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs) | 2023 | Pisacane, Alberto; Cascardi, Eliano; Berrino, Enrico; Polidori, Alessio; Sarotto, Ivana; Casorzo, Laura; Panero, Mara; Boccaccio, Carla; Verginelli, Federica; Benvenuti, Silvia; Dellino, Miriam; Comoglio, Paolo; Montemurro, Filippo; Geuna, Elena; Marchiò, Caterina; Sapino, Anna | |
| MET mutations in cancers of unknown primary origin (CUPs). | 2011 | G. M. Stella;S. Benvenuti;D. Gramaglia;A. Scarpa;A. Tomezzoli;P. Cassoni;R. Senetta;T. Venesio;E. Pozzi;A. Bardelli;P. M. Comoglio | |
| Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: An in vitro study | 2019 | Cova E.; Pandolfi L.; Colombo M.; Frangipane V.; Inghilleri S.; Morosini M.; Mrakic-Sposta S.; Moretti S.; Monti M.; Pignochino Y.; Benvenuti S.; Prosperi D.; Stella G.; Morbini P.; Meloni F. | |
| Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs) | 2023 | Pisacane, Alberto; Cascardi, Eliano; Berrino, Enrico; Polidori, Alessio; Sarotto, Ivana; Casorzo, Laura; Panero, Mara; Boccaccio, Carla; Verginelli, Federica; Benvenuti, Silvia; Dellino, Miriam; Comoglio, Paolo; Montemurro, Filippo; Geuna, Elena; Marchio', Caterina; Sapino, Anna | |
| Ron kinase transphosphorylation sustains MET oncogene addiction | 2011 | S. Benvenuti; L. Lazzari; A. Arnesano; G. Li Chiavi; A. Gentile; P.M. Comoglio | |
| Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis | 2011 | Gentile A; Lazzari L; Benvenuti S; Trusolino L*; Comoglio PM* (*Corresponding Authors) | |
| Targeting the MET oncogene in cancer and metastases. | 2010 | G. M. Stella;S. Benvenuti;P. M. Comoglio | |
| The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. | 2014 | Gentile A;Lazzari L;Benvenuti S;Trusolino L;Comoglio PM |